SIAIS178 demonstrated selective antiproliferative activity against BCR-ABL CML cells, but not in BCR-ABL negative leukaemia lines such as U937, HL-60, or HEK293 cells, highlighting its selectivity. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.